Lyndsay Wright

HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US.

Neusentis is a biopharmaceutical company, which is focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. The company has developed an integrated technology platform that allows for the efficient discovery of drug leads. The firm is conducting research and development activities in a number of disease areas, including epilepsy, pain and inflammation. Icagen has two clinical stage programs in epilepsy and pain. The company was formerly known as Icagen, Inc. It was founded by Andre L. Lamotte and P. Kay Wagoner on November 23, 1992 and is headquartered in Durham, NC.

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

University of Southern California is a private research university that mainly offers undergraduate, graduate & other higher education. The university was founded in 1880 and is headquartered in Los Angeles, CA.

Part of Perrigo Co. Plc, Creagen, Inc. is a biopharmaceutical development company. The private company is based in Cambridge, MA. The company was founded by André L. Lamotte, Roberto Crea. Creagen was acquired by Neurex Corp. on July 26, 1994 for $8.05 million.

Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland.

BioVex Ltd. operates as a biotechnology firm. It focuses on the development and commercialization of biological treatments for cancer and the prevention of infectious disease. The company was founded on December 15, 1997 and is headquartered in Cambridge, the United Kingdom.

MSD Vaccines Ltd. manufactures and supplies vaccines. Its main way of achieving this goal is to develop and make available innovative vaccines against a wide spectrum of diseases. It also dedicated to increasing the understanding of the value of vaccines and vaccination by providing relevant and accurate information on their quality, safety and efficacy. The company was founded in 1975 and is headquartered in Maidenhead, the United Kingdom.

Diatide, Inc. is a company based in Londonderry, NH. Diatide, Inc. was founded by André L. Lamotte.

Part of Moderna, Inc., Valera LLC is a private company that develops and markets vaccines. The company is based in Cambridge, MA.